Structure Therapeutics Appoints Angus C. Russell to Board of Directors Via Investing.com
Former CEO of Shire brings over 30 years of experience in building and growing companies in the global biopharmaceutical industry
SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a global clinical-stage biopharmaceutical company developing oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings over 30 years of experience in building and growing companies in the global biopharmaceutical industry.
Structure is at an important time in its evolution as we prepare to advance our small molecule oral GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity, said Raymond Stevens, Ph.D., Founder and CEO of Structure . Medicines. Angus is a seasoned biopharmaceutical leader with significant expertise across multiple corporate functions including strategy, finance, operations, and commercialization. His experience in building and growing companies will help lead us to our next chapter of growth as we continue to develop our comprehensive approach to oral small molecule therapeutics”all within our structure-based drug discovery”to make it accessible to all.
Structure of GSBR-1290, 2n.d and 3rd generation equipment, and next-generation oral implant systems have the potential to create a cycle of continuous innovation in the obesity market to meet the changing needs of millions of patients while increasing accessibility, said Mr. Russell. The leading structural program, GSBR-1290, is just the beginning in the important area of metabolism and obesity. I am very excited to join Structure's board of directors to help lead the company into the future.
Mr. Russell served as Chief Executive Officer of Shire plc, a biopharmaceutical company from June 2008 to April 2013, Chief Financial Officer of Shire from 1999 to 2008, and a member of the board of directors from 1999 to 2013. While CEO at Shire, Mr. . Russell was also Chairman of Shire's Leadership Team and a leading member of Shire's Management Committee, which designed and implemented the company's successful long-term business strategy. Before joining Shire, Mr. Russell worked at AstraZeneca (NASDAQ:) plc, a pharmaceutical and biologics company, most recently as VP of Corporate Finance. Mr. Russell served on the Board of Directors of Mallinckrodt (OTC:) from August 2014 to June 2022 and TherapeuticsMD (NASDAQ:), Inc. from March 2015 to December 2022. Mr. Russell currently serves as Chairman of the Board of Revance Therapeutics (NASDAQ:) and is a board member of Lineage Cell Therapeutics (NYSE:), Inc.
About Structure Therapeutics
Structure Therapeutics is a science-driven biopharmaceutical company focused on discovering and developing oral small molecule therapies for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Using a next-generation structure-based drug discovery platform, the Company has developed a robust GPCR-targeted pipeline, consisting of fully-targeted small molecule compounds designed to overcome the limitations of biologic and peptide therapies and are accessible to them. many patients around the world. For more information, please visit www.structuretx.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that may be considered forward-looking, including, without limitation, statements regarding: the Company's future plans and prospects; The strength of the Company's programs is to establish a cycle of continuous innovation in the obesity market to meet the changing needs of millions of patients while increasing accessibility. In addition, when or if used in this press release, the words and phrases expect, plan, potential, promising, existence, and similar expressions and their variations, as they relate to the Company may identify forward-looking statements. Forward-looking statements are not historical facts or guarantees of future performance. Although the Company believes that the expectations expressed in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be true. Readers are cautioned that actual results, levels of performance, safety, performance or events and conditions may differ materially from those expressed or implied in the Company's forward-looking statements due to various risks and uncertainties, including, without limitation, risks and uncertainties related to the Company's ability to continue GSBR-1290, LTSE -2578, ANPA-0073 and its other therapeutic candidates, have received regulatory approval and ultimately commercialized the Company's therapeutics, competitive products or methods that limit the commercial value of the Company's product candidates. , the timing and results of pre-clinical and clinical trials, the Company's ability to finance development activities and achieve development goals, the impact of any global pandemics, inflation, liquidity issues, rising interest rates and future bank failures on the Company's business, its ability. to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 8, 2024, Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024, and future reports that the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date they are made and are based on management's estimates and estimates as of that date. The Company undertakes no obligation to update such statements to reflect events occurring or conditions existing after the date they are made, except as required by law.
Investors:
Danielle Keatley
Company Structure Therapeutics, Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
